Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years

被引:93
作者
Kafali, G
Erselcan, T
Tanzer, F
机构
[1] Cumhuriyet Univ, Fac Med, Dept Pediat, Sivas, Turkey
[2] Cumhuriyet Univ, Fac Med, Dept Nucl Med, Sivas, Turkey
关键词
D O I
10.1177/000992289903800205
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
We assessed the effects of sodium valproate and carbamazepine monotherapy on bone mineral density (BMD) in children. BMD at the lumbar vertebrae (L-1-L-4) and radius-ulna was measured by the dual-energy x-ray absorptiometry (DEXA) method in 19 children (9 girls, 10 boys) with uncomplicated epilepsy and in 57 healthy children (28 girls, 29 boys), between the ages of 6 and 12 years. The study patients had been receiving either sodium valproate (n = 13) or carbamazepine (n = 6) monotherapy for more than 6 months. There were no significant differences between the control and study patients in age, height, weight, physical activity, or of serum concentrations of calcium, phosphate, and transaminases (aspartate aminotransferase, alanine aminotransferase). However, the serum alkaline phosphatase concentration was greater in the patient group as compared with the control group. BMD values were lower in girl patients (L-1-L-4; 0.497 +/- 0.08 vs 0.566 +/- 0.07 g/cm(2), p < 0.05), but not in boys (0.534 +/- 0.06 vs 0.530 +/- 0.08 g/cm(2)). While BMD reduction was 8% in valproate therapy (midregion of radius-ulna; 0.287 +/- 0.03 vs 0.312 +/- 0.04 g/cm(2), p < 0.04), it was reduced only 4.5% in the carbamazepine-treated group (0.298 +/- 0.01 vs 0.312 +/- 0.04 g/cm(2), statistically not significant), although the mean durations of monotherapy with valproate (1.8 +/- 0.7 years) and carbamazepine (1.7 +/- 0.8 years) were similar. Thus decreased bone mineralization was observed in children with epilepsy, treated with sodium valproate even though treatment was for a rather short time.
引用
收藏
页码:93 / 98
页数:6
相关论文
共 20 条
[1]   LONG-TERM ANTICONVULSANT THERAPY AND VITAMIN-D METABOLISM IN AMBULATORY PUBERTAL CHILDREN [J].
ALAHOUHALA, M ;
KORPELA, R ;
KOIVIKKO, M ;
KOSKINEN, T ;
KOSKINEN, M ;
KOIVULA, T .
NEUROPEDIATRICS, 1986, 17 (04) :212-216
[2]  
CHRISTIANSEN C, 1983, ACTA NEUROL SCAND, V67, P21
[3]   INCIDENCE OF ANTICONVULSANT OSTEOMALACIA AND EFFECT OF VITAMIN-D - CONTROLLED THERAPEUTIC TRIAL [J].
CHRISTIANSEN, C ;
RODBRO, P ;
LUND, M .
BMJ-BRITISH MEDICAL JOURNAL, 1973, 4 (5894) :695-701
[4]  
CROSLEY CJ, 1975, PEDIATRICS, V56, P52
[5]   FRACTURES CAUSED BY EPILEPTIC SEIZURES AND EPILEPTIC OSTEOMALACIA [J].
DUUS, BR .
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 1986, 17 (01) :31-33
[6]   BONE STATUS IN NONAMBULANT, EPILEPTIC, INSTITUTIONALIZED YOUTH - IMPROVEMENT WITH VITAMIN-D THERAPY [J].
FISCHER, MH ;
ADKINS, WN ;
LIEBL, BH ;
VANCALCAR, SC ;
MARLETT, JA .
CLINICAL PEDIATRICS, 1988, 27 (10) :499-505
[7]  
HAHN TJ, 1975, NEW ENGL J MED, V292, P550, DOI 10.1056/NEJM197503132921102
[8]   ANTICONVULSANT DRUG-INDUCED OSTEOMALACIA - ALTERATIONS IN MINERAL METABOLISM AND RESPONSE TO VITAMIN-D3 ADMINISTRATION [J].
HAHN, TJ ;
HALSTEAD, LR .
CALCIFIED TISSUE INTERNATIONAL, 1979, 27 (01) :13-18
[9]   BONE-DISEASE INDUCED BY ANTICONVULSANT THERAPY AND TREATMENT WITH CALCITRIOL (1,25-DIHYDROXYVITAMIN-D3) [J].
HUNT, PA ;
WUCHEN, ML ;
HANDAL, NJ ;
CHANG, CT ;
GOMEZ, M ;
HOWELL, TR ;
HARTENBERG, MA ;
CHAN, JCM .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1986, 140 (07) :715-718
[10]  
KECK E, 1982, EUR J PEDIATR, V139, P52, DOI 10.1007/BF00442080